257
Participants
Start Date
February 5, 2023
Primary Completion Date
July 1, 2024
Study Completion Date
July 1, 2024
Tirzepatide
Administered SC
Placebo
Administered SC
Beijing Hospital, Beijing
Beijing Pinggu District Hospital, Beijing
The First Hospital of Harbin Medical University, Harbin
The Fourth Hospital of Harbin Medical University, Harbin
Nanjing First Hospital, Nanjing
Zhongda Hospital Southeast University, Nanjing
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
Affiliated Hospital of Jiangsu University, Zhenjiang
Changzhou No.2 People's Hospital, Changzhou
Wuxi People's Hospital, Wuxi
The Affiliated Jiangyin Hospital of Southeast University Medical College, WuxiShi
The Second People's Hospital of Hefei, Hefei
Jinan Central Hospital, Jinan
Tianjin Medical University General Hospital, Tianjin
Huzhou Central Hospital, Huzhou
The Third Hospital of Nanchang, Nanchang
Chongqing General Hospital, Chongqing
The First People's Hospital of Yueyang, Yueyang
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of Science &Technology, LuoyangShi
Huizhou Municipal Central Hospital, Huizhou
West China Hospital of Sichuan University, Chengdu
Chengdu Fifth People's Hospital, Chengdu
The First Affiliated Hospital of Xi'an Medical University, Xi'an
Baotou Central Hospital, Baotou
Eli Lilly and Company
INDUSTRY